公司概覽
業務類別 Biotechnology
業務概覽 Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
公司地址 215 First Street, Suite 415, Cambridge, MA, USA, 02142
電話號碼 +1 617 274-4000
傳真號碼 +1 800 621-5203
公司網頁 https://www.sarepta.com
員工數量 835
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Michael Severino, M.D. Chief Executive Officer and Director -- 27/07/2026
Dr. Louise Rodino-Klapac, PhD President, Research and Development and Technical Operations 美元 752.51K 24/04/2026
Mr. Ian Michael Estepan President and Chief Operating Officer 美元 740.53K 24/04/2026
Ms. Cristin L. Rothfuss Executive Vice President, Chief General Counsel and Corporate Secretary 美元 629.86K 24/04/2026
Mr. Ryan H. Wong Executive Vice President, Chief Financial Officer and Principal Accounting Officer 美元 480.12K 24/04/2026
 
董事會成員
董事會 職務 更新日期
Ms. Deirdre P. Connelly Independent Director 24/04/2026
Dr. M. Kathleen Behrens Wilsey, PhD Chairwoman of the Board 24/04/2026
Dr. Claude Nicaise,M.D. Independent Director 24/04/2026
Dr. Hans Wigzell, M.D.,PhD Independent Director 24/04/2026
Mr. Richard J. Barry Independent Director 24/04/2026
Dr. Michael Severino, M.D. Chief Executive Officer and Director 27/07/2026
Dr. Kathryn Jean Boor, PhD Independent Director 24/04/2026
Dr. Stephen L. Mayo, PhD Independent Director 24/04/2026
Mr. Michael A. Chambers Independent Director 24/04/2026
 
所屬ETF (更新日期: 14/11/2026 03:45)
代號 名稱 佔比% ▼ 持有日期
JUSAJPMorgan ActiveBuilders US Lg Cp Eq ETF0.0002%31/08/2023
FSEGFidelity Enhanced Small Cap Growth ETF0.0002%30/10/2026
RESMColumbia Research Enhanced Small Cap ETF0.0002%31/10/2026
AVSUAvantis Responsible US Equity ETF0.0002%30/10/2026
HDGProShares Hedge Replication0.0001%30/10/2026
AVIEAvantis Inflation Focused Equity ETF0.0001%30/10/2026
RBProshares Russell 2000 Dynamic BufferETF0.00003%30/10/2026
FEMGFidelity Enhanced Mid Cap Growth ETF0.00002%30/10/2026
MMTMState Street® SPDR® S&P® 1500MomtTiltETF0.00001%30/10/2026
EBILongview Advantage ETF0.000004%30/10/2026
AVKAdvent Convertible & Income Fund<0.000001%31/07/2025
BALIiShares U.S. Large Cap Prm Inc Act ETF<0.000001%01/08/2025
BKMCBNY Mellon US Mid Cap Core Equity ETF<0.000001%07/08/2025
CDXSimplify High Yield ETF<0.000001%30/09/2026
FADFirst Trust Multi Cap Gr AlphaDEX® ETF<0.000001%07/10/2026
FBTFirst Trust NYSE Arca Biotech ETF<0.000001%18/10/2026
FLCCFederated Hermes MDT Large Cap Core ETF<0.000001%15/08/2025
FRTYAlger Mid Cap 40 ETF<0.000001%25/08/2025
FSMDFidelity Small-Mid Multifactor ETF<0.000001%15/08/2025
FTQIFirst Trust Nasdaq BuyWrite Income ETF<0.000001%27/08/2025
  1    2    3    4    5   6    7  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.